Cell line · CVCL_2529
Papers61
1 to 20 of 61
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Fluoxetine Is Associated with Reduced Cell Viability and Decreased pERK1/2 Immunoreactivity in Ishikawa Endometrial Cancer Cells In Vitro: An Exploratory Study. | Life (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Agmatine Sulfate Is Associated with Altered Redox Status, Apoptosis-Associated Responses, and AKT/JNK Signalling in Ishikawa Endometrial Cancer Cells. | Life (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integration of Spatial Transcriptomics and Mendelian Randomization Identifies Candidate Molecular Regulators of Endometrial Cancer Progression. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer-relevant paralog interplay. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lithium Chloride-Induced Nuclear Envelope Remodeling in 3D Endometrial Cancer Spheroids. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Steroid-Metabolizing Enzymes with 15β-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17β-HSD1 Inhibitors and a Fluorescent 17β-HSD1 Ligand. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Large-Scale Quantitative Morphometry of Platelet α-Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial Injury Accompanied by Intermediate Filament Remodeling Following Lithium Chloride Exposure in 3D Endometrial Cancer Spheroids. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multifaceted role of POU5F1P1 in regulating its parental stem cell gene, POU5F1. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NSD1-Mediated PPARγ Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lipid-Driven OLR1/FOXM1/FGF19 Axis Orchestrates Crosstalk in an Epithelial-Fibroblast Positive Feedback Promoting Progesterone Resistance in Endometrial Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined Hesperidin and Gemcitabine Therapy Modulates Apoptosis and Angiogenesis Pathways in ISHIKAWA Human Endometrial Adenocarcinoma Cells. | Medicina (Kaunas) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NRDR Inhibits the Migration of Endometrial Cancer Cells and Affects Their Gene Expression. | Scientifica (Cairo) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| GWAS meta-analysis identifies five susceptibility loci for endometrial cancer. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Assessment of NUDT5 in Endometrial Carcinoma: Functional Insights, Prognostic and Therapeutic Implications. | Biomedicines | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2529/papers